



I-Tech announces a one year extension of the current EU Approval for Selektope (Medetomidine)

I-Tech AB, developers of the innovative antifouling technology Selektope, announce that the current approval for Selektope (Medetomidine) in the European Union has been extended by one year. This extension is part of the normal procedures as the EU Commission continues its thorough re-registration process.

The re-registration process in the EU involves a comprehensive review to ensure that all substances meet stringent safety and environmental standards. As part of this process, a public consultation was conducted, during which I-Tech received substantial support from various stakeholders. This positive feedback underscores the confidence in Selektope's efficacy and safety.

While the EU Commission's decision is taking longer than initially anticipated, I-Tech views this extension positively.

I-Tech's CEO, Markus Jönsson comments:

"The new extension reflects the importance of a well-considered decision that takes into account all public consultation opinions. We believe that this careful approach will ultimately benefit both the environment and the maritime industry. We keep working actively on informing decision makers and interest groups about why Selektope is important for use in the EU and we stay hopeful that member states will reach a positive decision by the end of 2025."

Contacts

Markus Jönsson, CEO

M: +46729-77 96 25

E: markus.jonsson@i-tech.se

About I-Tech AB

I-Tech is a biotechnology company that has developed the antifouling technology Selektope®, an active substance that prevents barnacle attachment on submerged surfaces such as ships and boat hulls. By increasing the anti-barnacle performance in marine paint systems (e.g. antifouling coatings), fuel and maintenance costs are reduced and vessel energy efficiency improved. I-Tech has obtained the necessary regulatory approvals for Selektope® and has several of the world's largest manufacturers of marine antifouling coatings as customers. The company's share is listed for trading on Nasdaq First North Growth Market in Stockholm. The Company's Certified Adviser is DNB Carnegie Investment Bank AB. For more information visit our website www.i-tech.se.

Attachments

[I-Tech announces a one year extension of the current EU Approval for Selektope \(Medetomidine\)](#)